GlaxoSmithKline
5 Crescent Drive
Philadelphia
Pennsylvania
19112
United States
Tel: 888-825-5249
Website: http://www.gsk.com/
About GlaxoSmithKline
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2787 articles with GlaxoSmithKline
-
Axovant Sciences, one of Vivek Ramaswamy’s biotech companies under the Roivant Sciences’ umbrella, is forming a company called Arvelle Therapeutics. Arvelle is a strategic transition of Axovant’s legacy small molecule team.Biopharmaceuticals
-
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
-
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
-
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Ac...
2/8/2019
Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation. -
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here's the latest edition.
-
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
-
GlaxoSmithKline has been in the midst of a significant reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company has made some cuts to its pipeline, including six quietly announced this morning in the company’s year-end report.
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.
-
Shares of GlaxoSmithKline took a slight dip Wednesday afternoon after the U.S. Food and Drug Administration approved Mylan NV’s generic version of Advair Diskus, a staple blockbuster drug in the U.K. pharmaceutical company’s pipeline.
-
Since taking over the helm of GlaxoSmithKline in 2017, Chief Executive Officer Emma Walmsley has made some significant moves to redefine the company as one focused on the development of pharmaceuticals.
-
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
1/22/2019
GlaxoSmithKline plc today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
-
Hampton has served as chairman of the board since 2015. He decided to part ways with the company as it plans to separate into two entities.
-
GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative
1/8/2019
Collaboration between key players in the pharmaceutical, biotechnology and healthcare fields fortifies responsible business practices and shared value within global health supply chain
-
Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
-
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
-
Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company
12/19/2018
Establishes a new focused global consumer healthcare business with the independence and sustainability to deliver significant value
-
Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regula...